^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fluorobenzyl polyethylene glycol mono-triazole tetraiodothyroacetic acid (fb-PMT)

    i
    Other names: fb-PMT, NP751, NP-100
    Associations

    News

    Trials
    Company:
    NanoPharmaceuticals
    Drug class:
    αvβ3 integrin antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=34, Recruiting, NanoPharmaceuticals LLC | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    fluorobenzyl polyethylene glycol mono-triazole tetraiodothyroacetic acid (fb-PMT)
    over2years
    Preclinical Assessment of Drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist. (PubMed, Clin Transl Sci)
    However, fb-PMT inhibited the uptake of rosuvastatin by both OATP1B1 and OATP1B3 with IC s >3 and <10 μM. In summary, data suggest that the systemic administration of fb-PMT is unlikely to lead to DDIs through CYP enzymes or ABC and SLC transporters in humans.
    Preclinical • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    fluorobenzyl polyethylene glycol mono-triazole tetraiodothyroacetic acid (fb-PMT)